Phospho-PPP1R14A (T38) Antibody

What is PPP1R14A and why is its phosphorylation at T38 significant?

PPP1R14A (also known as CPI-17) functions as an inhibitor of protein phosphatase 1 (PP1). When phosphorylated at threonine 38 (T38), its inhibitory activity increases over 1000-fold, creating a molecular switch that regulates the phosphorylation status of PPP1CA substrates and smooth muscle contraction . This dramatic increase in inhibitory potency makes the T38 phosphorylation site particularly important for studying PPP1R14A's biological functions and roles in disease pathways.

What detection methods are available for studying Phospho-PPP1R14A (T38)?

Multiple validated detection methods exist for studying Phospho-PPP1R14A (T38):

When selecting a method, researchers should consider the specific experimental question, sample type, and required sensitivity. For spatial distribution studies, IHC or IF are recommended, while WB provides better quantitative information about expression levels.

How should samples be prepared to preserve the phosphorylation at T38?

Phosphorylation states are highly labile and require specific handling:

• Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all buffers from the moment of sample collection

• Keep samples cold (4°C or on ice) throughout processing

• Use rapid fixation protocols for tissue samples to prevent dephosphorylation

• Consider using specialized phosphoprotein preservation buffers

• Process samples immediately after collection; avoid freeze-thaw cycles

These steps are critical as studies have shown significantly decreased phosphorylation levels of PPP1R14A at sites including T38 in various tumor samples compared to normal tissues, which could be either biologically relevant or a technical artifact of sample handling .

What controls are essential when using Phospho-PPP1R14A (T38) antibodies?

A comprehensive control strategy should include:

• Positive control: Samples known to express phosphorylated PPP1R14A, such as PKC-activated smooth muscle cells

• Negative control: Samples treated with phosphatase to remove phosphorylation

• Competing peptide control: Pre-incubation of antibody with the immunizing phosphopeptide should abolish signal

• Non-phosphorylated protein control: Samples containing only the non-phosphorylated form

• Total protein control: Parallel detection with an antibody recognizing total PPP1R14A regardless of phosphorylation state

As demonstrated in immunohistochemistry experiments, pre-incubation with the immunizing phosphopeptide completely abolished the signal in human breast carcinoma tissues, confirming antibody specificity .

How can researchers optimize antibody dilutions for different applications?

Optimal antibody dilutions vary by application and manufacturer. Based on available data:

For novel sample types, a dilution series is recommended. Begin with the manufacturer's suggested range and perform a titration experiment to determine optimal signal-to-noise ratio. Multiple commercially available antibodies have been validated for human, mouse, and rat samples .

What signaling pathways affect PPP1R14A phosphorylation at T38?

PPP1R14A phosphorylation at T38 is primarily regulated by:

• PKC pathway: The primary kinase responsible for T38 phosphorylation

• Ras signaling: Downregulation of CPI-17 induces merlin dephosphorylation, thereby inhibiting Ras activation

• Carcinogenic pathways: Pan-cancer analysis shows altered phosphorylation of T38 in multiple cancer types

When designing experiments to study PPP1R14A phosphorylation, consider including activators or inhibitors of these pathways as experimental controls. For example, PKC activators like phorbol esters can serve as positive controls for T38 phosphorylation.

How does Phospho-PPP1R14A (T38) expression correlate with cancer prognosis?

Comprehensive pan-cancer analysis has revealed significant correlations between PPP1R14A expression and patient outcomes:

These findings suggest PPP1R14A phosphorylation status could serve as a prognostic biomarker, but further research is needed to establish standardized detection methods for clinical applications.

What is the relationship between PPP1R14A genetic alterations and its phosphorylation?

The frequency of PPP1R14A genetic changes (mutations and copy number alterations) varies across cancer types, with the highest frequency (16.07%) observed in uterine carcinosarcoma . These alterations correlate with:

• Poor survival outcomes in multiple cancer types

• Altered phosphorylation patterns, particularly at key sites including T38

• Changes in downstream signaling pathway activation

Researchers investigating phosphorylation status should consider sequencing PPP1R14A to identify potential mutations that might affect antibody binding or phosphorylation site accessibility. Novel mutations near the T38 site could explain discrepancies in phosphorylation detection across different studies.

How does PPP1R14A phosphorylation affect immune infiltration in cancer?

Recent research has uncovered significant correlations between PPP1R14A expression and immune cell infiltration:

• PPP1R14A expression significantly associates with infiltrating immune cells, including:

  • B cells in 14 types of cancer

  • CD4+ T cells in 18 types of cancer

  • CD8+ T cells in multiple cancer types

• PPP1R14A expression correlates with levels of immune checkpoint genes

This relationship suggests that phosphorylation status of PPP1R14A may influence the tumor immune microenvironment, potentially affecting responses to immunotherapy. When designing studies examining PPP1R14A phosphorylation in tumor samples, researchers should consider concurrent analysis of immune cell markers to explore these associations.

How can researchers differentiate between phosphorylated and non-phosphorylated forms of PPP1R14A?

Several strategies can help distinguish between phosphorylated and non-phosphorylated forms:

• Phosphatase treatment controls: Treat duplicate samples with lambda phosphatase prior to analysis

• Mobility shift analysis: Phosphorylated PPP1R14A often migrates slightly slower on SDS-PAGE

• Parallel detection: Use both phospho-specific and total PPP1R14A antibodies on parallel samples

• Phos-tag™ SDS-PAGE: This technique enhances the mobility shift of phosphorylated proteins

• 2D gel electrophoresis: Separate proteins by both isoelectric point and molecular weight

For confounding results, mass spectrometry analysis can provide definitive identification of phosphorylation sites and stoichiometry.

What strategies can overcome weak Phospho-PPP1R14A (T38) signal in Western blots?

When encountering weak signals for Phospho-PPP1R14A (T38):

• Optimize sample preparation:

  • Ensure complete protease and phosphatase inhibition

  • Consider phosphatase treatment of control samples to confirm specificity

  • Use fresh samples where possible

• Optimize detection conditions:

  • Try different blocking agents (BSA vs. milk proteins)

  • Increase antibody concentration or incubation time

  • Use enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Consider signal amplification systems

• Modify transfer conditions:

  • Optimize transfer time and voltage

  • Use PVDF membranes instead of nitrocellulose for better protein retention

  • Consider wet transfer for small proteins like PPP1R14A (17 kDa)

These approaches have proven effective in detecting low-abundance phosphoproteins across multiple experimental systems.

How can methylation status affect PPP1R14A detection?

Studies have shown enhanced methylation within the promoter region of PPP1R14A DNA in a majority of cancers . This methylation can affect:

When studying PPP1R14A phosphorylation in cancer samples, consider:

• Analyzing promoter methylation status in parallel

• Correlating methylation patterns with protein expression and phosphorylation

• Using cell lines with known methylation status as controls

This integrated approach provides more comprehensive insights into the regulatory mechanisms affecting PPP1R14A phosphorylation.

How should researchers interpret contradictory findings regarding Phospho-PPP1R14A (T38)?

Pan-cancer analyses have revealed complex patterns of PPP1R14A expression and phosphorylation:

• PPP1R14A is downregulated in major malignancies including BLCA, BRCA, COAD, KICH, KIRP, LUAD, LUSC, PRAD, READ, STAD, and UCEC, but upregulated in CHOL, HNSC, and LIHC

• Phosphorylation patterns show tissue-specific variations:

  • T38 phosphorylation decreased in colon cancer

  • S26 phosphorylation decreased in multiple cancers but increased in KIRC

  • Complex patterns at other phosphorylation sites (S101, S103, S107, S109)

When encountering contradictory findings:

• Consider tissue-specific regulatory mechanisms

• Examine methodological differences between studies

• Analyze cancer subtypes and patient stratification

• Integrate data across multiple phosphorylation sites

These approaches help reconcile apparently contradictory findings and develop more nuanced understanding of PPP1R14A biology.

What are the implications of PPP1R14A phosphorylation for precision medicine?

The significant correlation between PPP1R14A expression, phosphorylation status, and patient outcomes suggests potential applications in precision medicine:

• Diagnostic applications:

  • ROC analysis shows PPP1R14A has high reference significance in diagnosing a variety of cancers

  • Phosphorylation status at T38 and other sites may provide additional diagnostic specificity

• Prognostic applications:

  • Pan-cancer survival analysis indicates PPP1R14A expression correlates with OS, DSS, and PFI across multiple cancers

  • Phosphorylation patterns may refine prognostic indicators

• Therapeutic implications:

  • As a modulator of PP1 activity, targeting PPP1R14A phosphorylation could represent a novel therapeutic approach

  • Correlations with immune checkpoint genes suggest potential relevance to immunotherapy response prediction

Researchers should consider integrating phosphorylation analysis of multiple sites (not just T38) for more comprehensive biomarker development.